Obesity, a pandemic of the modern world, is intimately associated with dyslipidemia, which is mainly driven by the effects of insulin resistance and pro-inflammatory adipokines. However, recent evidence suggests that obesity-induced dyslipidemia is not a unique pathophysiological entity, but rather has distinct characteristics depending on many individual factors. In line with that, in a subgroup of metabolically healthy obese (MHO) individuals, dyslipidemia is less prominent or even absent. In this review, we will address the main characteristics of dyslipidemia and mechanisms that induce its development in obesity. The fields, which should be further investigated to expand our knowledge on obesity-related dyslipidemia and potentially yield new strategies for prevention and management of cardiometabolic risk, will be highlighted. Also, we will discuss recent findings on novel lipid biomarkers in obesity, in particular proprotein convertase subtilisin/kexin type 9 (PCSK9), as the key m...olecule that regulates metabolism of low-density lipoproteins (LDL), and sphingosine-1-phosphate (S1P), as one of the most important mediators of high-density lipoprotein (HDL) partides function. Special attention will be given to microRNAs and their potential use as biomarkers of obesity-associated dyslipidemia.
TY - JOUR
AU - Vekić, Jelena
AU - Zeljković, Aleksandra
AU - Stefanović, Aleksandra
AU - Jelić-Ivanović, Zorana
AU - Spasojević-Kalimanovska, Vesna
PY - 2019
UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3349
AB - Obesity, a pandemic of the modern world, is intimately associated with dyslipidemia, which is mainly driven by the effects of insulin resistance and pro-inflammatory adipokines. However, recent evidence suggests that obesity-induced dyslipidemia is not a unique pathophysiological entity, but rather has distinct characteristics depending on many individual factors. In line with that, in a subgroup of metabolically healthy obese (MHO) individuals, dyslipidemia is less prominent or even absent. In this review, we will address the main characteristics of dyslipidemia and mechanisms that induce its development in obesity. The fields, which should be further investigated to expand our knowledge on obesity-related dyslipidemia and potentially yield new strategies for prevention and management of cardiometabolic risk, will be highlighted. Also, we will discuss recent findings on novel lipid biomarkers in obesity, in particular proprotein convertase subtilisin/kexin type 9 (PCSK9), as the key molecule that regulates metabolism of low-density lipoproteins (LDL), and sphingosine-1-phosphate (S1P), as one of the most important mediators of high-density lipoprotein (HDL) partides function. Special attention will be given to microRNAs and their potential use as biomarkers of obesity-associated dyslipidemia.
PB - W B Saunders Co-Elsevier Inc, Philadelphia
T2 - Metabolism-Clinical and Experimental
T1 - Obesity and dyslipidemia
VL - 92
SP - 71
EP - 81
DO - 10.1016/j.metabol.2018.11.005
ER -
@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna",
year = "2019",
abstract = "Obesity, a pandemic of the modern world, is intimately associated with dyslipidemia, which is mainly driven by the effects of insulin resistance and pro-inflammatory adipokines. However, recent evidence suggests that obesity-induced dyslipidemia is not a unique pathophysiological entity, but rather has distinct characteristics depending on many individual factors. In line with that, in a subgroup of metabolically healthy obese (MHO) individuals, dyslipidemia is less prominent or even absent. In this review, we will address the main characteristics of dyslipidemia and mechanisms that induce its development in obesity. The fields, which should be further investigated to expand our knowledge on obesity-related dyslipidemia and potentially yield new strategies for prevention and management of cardiometabolic risk, will be highlighted. Also, we will discuss recent findings on novel lipid biomarkers in obesity, in particular proprotein convertase subtilisin/kexin type 9 (PCSK9), as the key molecule that regulates metabolism of low-density lipoproteins (LDL), and sphingosine-1-phosphate (S1P), as one of the most important mediators of high-density lipoprotein (HDL) partides function. Special attention will be given to microRNAs and their potential use as biomarkers of obesity-associated dyslipidemia.",
publisher = "W B Saunders Co-Elsevier Inc, Philadelphia",
journal = "Metabolism-Clinical and Experimental",
title = "Obesity and dyslipidemia",
volume = "92",
pages = "71-81",
doi = "10.1016/j.metabol.2018.11.005"
}
Vekić, J., Zeljković, A., Stefanović, A., Jelić-Ivanović, Z.,& Spasojević-Kalimanovska, V.. (2019). Obesity and dyslipidemia. in Metabolism-Clinical and Experimental
W B Saunders Co-Elsevier Inc, Philadelphia., 92, 71-81.
https://doi.org/10.1016/j.metabol.2018.11.005
Vekić J, Zeljković A, Stefanović A, Jelić-Ivanović Z, Spasojević-Kalimanovska V. Obesity and dyslipidemia. in Metabolism-Clinical and Experimental. 2019;92:71-81.
doi:10.1016/j.metabol.2018.11.005 .
Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, "Obesity and dyslipidemia" in Metabolism-Clinical and Experimental, 92 (2019):71-81,
https://doi.org/10.1016/j.metabol.2018.11.005 . .
